[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurodegenerative-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurodegenerative-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,49,115,148,208,255,296,333,358,386,410,438],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":4,"leadSponsor":45,"locationsCount":48},"100078073","the-neurodevelopmental-and-behavioral-phenotyping-screening-protocol-100078073",false,"NCT00271622","The Neurodevelopmental and Behavioral Phenotyping Screening Protocol","Neurodevelopmental and Behavioral Phenotyping Screening Protocol","* INCLUSION CRITERIA:\n* Subjects must be at least 6 weeks of age.\n* Subjects or their parents must be competent to comprehend the purpose of the screening process and to provide written informed consent. Parents\u002Fguardians will sign the consent form, and both minors and adults (depending on results of capacity assessment) will be asked to assent only if it is determined that they understand their role in the study.\n* Subjects must be willing to undergo an evaluation which may include a psychiatric interview; and medical, neurological, and laboratory examinations (as appropriate, such as renal and liver function tests, serum electrolytes, urinalysis, blood levels of psychotropic drugs, and urine drug screen for the presence of psychoactive drugs and drugs of abuse, as determined on a subject-to-subject basis).\n\nEXCLUSION CRITERIA:\n\n-Lack of appropriate consent: For minor patients, consent must be obtained from all legal guardians\u002Fcaretakers, including both parents in separated or divorced families where there is shared legal custody of the child. In such cases, both parents must consent to the child s participation in this protocol.",true,"ALL","6 Weeks",{"count":20,"type":21},5000,"ESTIMATED","OBSERVATIONAL","The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH.",[25,26,27,28],"Neurologic Disorders","Autism","Neurodegenerative Disease","Neurobehavioral Manifestation",[30,31,32,33,34,35,36,37],"Developmental Delay","Pediatric","Pervasive Developmental Disorder","Early Development","Healthy Control Subjects","Autism Spectrum Disorders","Healthy Volunteer","HV","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-25","ACTUAL",{"date":44,"type":42},"2006-02-27",{"name":46,"class":47},"National Institute of Mental Health (NIMH)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":80,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":48},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).","18 Years",{"count":59,"type":21},1000000,"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[62,63,64,65,66,67,68,69,70,71,27,72,73,74,75,76,77,78,79],"Aging","Mortality","All-cause Mortality","Life Expectancy","Cardiovascular Diseases","Neoplasms","Cognitive Dysfunction","Metabolic Syndrome","Frailty","Musculoskeletal Disease","Dementia","Activities of Daily Living","Health Related Quality of Life","Disability Physical","Environmental Exposure","Occupational Diseases","Health Equity","Social Determinants of Health",[81,82,83,84,85,86,87,88,89,90,91,92,93,78,94,95,96,97,98,99,100,101,102,103,104],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Healthspan","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model","2026-06-09",{"date":107,"type":42},"2026-06-15",{"date":109,"type":42},"2026-04-25",{"date":111,"type":21},"2099-12-31",{"name":113,"class":114},"Longevity Metrics, Inc.","INDUSTRY",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":135,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":48},"100579202","dyadic-mindfulness-for-people-with-parkinsons-disease-and-their-caregivers-100579202","NCT06821230","Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers","Enhancing Psychological Wellbeing and the Patient-caregiver Relationship Through Dyadic Mindfulness: A Randomized Controlled Trial in People With Parkinson's Disease and Their Caregivers","Inclusion Criteria of PwPD:\n\n* Chinese patients with idiopathic mild-moderate PD (as indicated by the Hoehn and Yahr Scale stages I-III: those with unilateral\u002Fbilateral symptoms, with\u002Fwithout postural instability who are able to walk\u002Fstand unassisted)\n* Aged ≥18 years\n\nInclusion Criteria of caregivers of PwPD:\n\n\\- Self-identified as the primary caregivers of their patient\n\nEither patient or caregiver needs to experience at least mild negative emotions (as indicated by the 21-item Depression, Anxiety and Stress Scale \\[DASS21\\] score of Depression subscale ≥10, Anxiety subscale ≥8, or Stress subscale ≥15)\n\nBoth need to be able to communicate in Cantonese and provide written consent.\n\nExclusion Criteria:\n\n* Engage in regular supervised mind-body practices such as Tai Chi, yoga, or other forms of mindfulness training (\\>2 times per week)\n* Have a pre-existing acute psychotic disease\n* Currently participating in any other behavioral or pharmacological trial\n* Have significant cognitive impairment, as indicated by an Abbreviated Mental Test score≤ 6\n* Have other contraindications that may limit their full participation (e.g., severe hearing\u002Fvision impairment)",{"count":123,"type":21},200,"INTERVENTIONAL",[126],"NA","The proposed two-arm randomized waitlist-controlled trial will use a mixed-methods design to investigate the effects of dyadic mindfulness on physio-psycho-spiritual outcomes in people with Parkinson's Disease (PwPD) and their family caregivers. One hundred Chinese patient-caregiver dyads will be randomized to receive eight weekly 90-minute dyadic mindfulness sessions or usual care. Outcome measures include negative emotions (primary outcome), patient-caregiver relationship, mindfulness, HRQOL, gut microbiome, PD-related symptoms, and caregiving burden. An actor-partner interdependence model will be used to explore the interactions of treatment effects within the dyads. The dyads will be assessed at baseline(T0), post-intervention(T1), and 4-months post-intervention(T2). The investigators will also invite 25 dyads to attend in-depth interviews exploring their experiences, perceived changes, and factors attributable to the effectiveness\u002Fineffectiveness of the intervention. Generalized linear mixed-effects (GLME) with intention-to-treat analysis will be used to compare the changes in outcomes over time within and between the two arms. The findings will be triangulated to provide a comprehensive evaluation of the intervention's effectiveness. This study will generate rigorous scientific evidence to inform the application of dyadic mindfulness as a public health practice preventing the progression of psychological distress in PwPD and caregivers to clinically severe levels. Its self-help nature also enriches the primary care for this clinical cohort.",[129,130,131,27,132,133,134],"Mindfulness","Caregivers","Movement Disorders","Dyadic Intervention","Psychosocial Health","Parkinsons Disease",[136,129,137],"Parkinsons disease","dyadic care","2026-05-28",{"date":140,"type":42},"2026-06-01",{"date":142,"type":42},"2025-02-11",{"date":144,"type":21},"2027-06-30",{"name":146,"class":147},"The University of Hong Kong","OTHER",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":124,"phases":158,"briefSummary":160,"conditions":161,"keywords":181,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","85 Years",{"count":157,"type":21},60,[159],"PHASE3","This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[162,163,27,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[182,173,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","2026-04-13",{"date":200,"type":42},"2026-04-16",{"date":202,"type":42},"2024-11-22",{"date":204,"type":21},"2028-08",{"name":206,"class":114},"Intellia Therapeutics",14,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":16,"sex":17,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":48},"100633056","div-ad-barcelona-alzheimers-blood-based-biomakers-for-a-diverse-community-100633056","NCT07521722","DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community","DIV-AD","INCLUSION CRITERIA\n\n* Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent\n* Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.\n* Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.\n* Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.\n\nEXCLUSION CRITERIA\n\n* Cognitive decline defined by CDR\\>0.\n* Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life\n* Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance\u002Finterpretation of the study procedures and\u002For with future permanence in the study.\n* Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).\n* Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).\n* Parkinson's disease, epilepsy under treatment and with frequent seizures (\\> 1\u002Fmonth) in the last year, multiple sclerosis or other neurodegenerative diseases.","50 Years","75 Years",{"count":218,"type":21},250,"The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.\n\nIt will also examine how factors such as age, income, education, and health conditions may affect these levels.\n\nIn addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.\n\nThe final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.",[221,222,72,27],"Alzheimer Disease","Cognitive Dysfunction, Cognitive Disorder",[224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245],"Alzheimer's disease","AD","Blood-based biomarkers","Plasma biomarkers","Phosphorylated tau","Amyloid beta","Neurofilament light chain","GFAP","Ethnic diversity","Health disparities","Cognitively unimpaired","Preclinical Alzheimer's disease","Primary care","Dementia prevention","Cross-cultural cognitive assessment","RUDAS","Dementia knowledge","Dementia stigma","Genetic ancestry","Migrant populations","Health equity","Diversity","NOT_YET_RECRUITING","2026-04-07",{"date":198,"type":42},{"date":250,"type":21},"2026-04-27",{"date":252,"type":21},"2029-01-01",{"name":254,"class":147},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":264,"conditions":265,"keywords":270,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100581157","exploring-the-olfactory-mucosa-blood-and-urine-for-the-identification-of-early-biomarkers-of-parkinsons-disease-atypical-parkinsonisms-and-neurocognitive-disorders-due-to-lewy-body-disease-100581157","NCT06846658","Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease","EXTRAORDINARY","Inclusion Criteria:\n\n* PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.\n\nExclusion Criteria:\n\n* na",{"count":263,"type":21},180,"Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages. Each disease is associated with distinct conformers of misfolded alpha-synuclein (maS) which form typical protein aggregates in the brain and represent key disease biomarkers. Thus, detection and characterization of intracerebral maS aggregates allow a definite diagnosis. The recent development of ultrasensitive assays enabled the detection of maS and other potential new biomarkers in peripheral tissues, although with several limitations. Here, the investigators propose to combine the expertise of leading and young researchers in the field of neurology, structural and molecular biology, biophysics and machine learning to perform ultrasensitive and multi-omics analyses of olfactory mucosa (OM), blood and urine of PD, MSA and DLB patients for detecting and characterizing key peripheral biomarkers allowing accurate disease recognition.",[266,267,268,27,269],"Parkinson Disease","MSA - Multiple System Atrophy","Lewy Body Dementia (LBD)","Healthy Subjects (HS)",[271,272,273,274,275,276,277,278,279,280,281,282,283,284,285],"Parkinson's disease (PD)","multiple system atrophy (MSA)","dementia with Lewy bodies (DLB)","misfolded alpha-synuclein","new biomarkers","peripheral tissues","Real-Time Quaking-Induced Conversion (RT-QuIC)","single-molecule array (Simoa)","circulating neurofilament light chain (NfL)","Nanoparticle Tracking Analysis (NTA)","blood-derived extracellular vesicles (EVs)","multi-omics analyses","transmission electron microscopy (TEM) and protein-NMR","protein misfolding","early diagnosis","2026-03-25",{"date":288,"type":42},"2026-03-30",{"date":290,"type":42},"2023-10-03",{"date":292,"type":21},"2026-04",{"name":294,"class":147},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",3,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":16,"sex":17,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":124,"phases":308,"briefSummary":309,"conditions":310,"keywords":317,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":48},"100620766","deciphering-the-effect-of-moderate-wine-consumption-on-healthy-aging-through-postprandial-extracellular-vesicles-100620766","NCT07361887","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.","Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles","(WINEVOME)","Inclusion Criteria\n\n* Healthy adult men and women aged 35 to 65 years.\n* Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n* Non-smokers or ex-smokers for at least 12 months.\n* Moderate alcohol consumers, defined as ≤2 units\u002Fday for men and ≤1 unit\u002Fday for women.\n* Normal fasting glucose and lipid profile at screening.\n* Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria\n\n* History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension).\n* Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, corticosteroids, anti-inflammatory drugs).\n* Pregnancy or breastfeeding.\n* Recent blood donation (within the last 3 months) or planned blood donation during the study period.\n* Major weight change (\\>5% of body weight) within the last 3 months.\n* Participation in another clinical or biomedical study within the previous 3 months.\n* Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites).\n* History of alcohol abuse or inability to abstain from alcohol outside the study context.\n* Reluctance to receive information about incidental health findings arising from the study.\n* Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).","35 Years","36 Years",{"count":307,"type":21},8,[126],"This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.",[311,312,69,313,314,315,27,316],"Atherosclerosis Cardiovascular Disease","Obesity","Metabolic Disorders","Inflammation","Neurodegeneration","Alzheimer s Disease",[318,319,320,321,322,323],"blood-brain barrier","microglia","extracellular vesicles","lipidome","proteome","vascular disease","2026-01-14",{"date":326,"type":42},"2026-01-23",{"date":328,"type":42},"2025-11-01",{"date":330,"type":21},"2027-03-31",{"name":332,"class":147},"University of Seville",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":339,"enrollmentInfo":340,"targetDuration":342,"studyType":22,"phases":4,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":357},"100616514","18fnidf-pet-imaging-in-tau-related-diseases-100616514","NCT07306598","[18F]NIDF PET Imaging in Tau-related Diseases","Inclusion Criteria:\n\n1. Between 18 and 90 years old;\n2. No gender limitation;\n3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases;\n4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes;\n5. Informed consent signed in person by the subject or his legal guardian or caregiver.\n\nExclusion Criteria:\n\n1. Has allergy to \\[18F\\]NIDF or any of its excipients;\n2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;\n3. Unwilling or unable to undergo PET scans tracer injections;\n4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection\u002Fanalysis of the data (e.g., renal or liver failure, advanced cancer);\n5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear);\n6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases;\n7. Women who are currently pregnant or breastfeeding.","90 Years",{"count":341,"type":21},20,"7 Days","In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents.\n\nThis clinical research project aims to visualize abnormal tau pathology in the living human brain using \\[18F\\]NIDF PET imaging. \\[18F\\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific\u002Foff-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \\[18F\\]NIDF PET imaging in human subjects.",[27,316,345],"Tauopathies",[347,224,348,345],"PET\u002FCT","Tau pathologies","2025-12-14",{"date":351,"type":42},"2025-12-29",{"date":328,"type":42},{"date":354,"type":21},"2030-12-01",{"name":356,"class":147},"Tianjin Medical University",2,{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":124,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":48},"100614927","mindfulness-walking-intervention-to-enhance-resilience-iwalk-100614927","NCT07285954","Mindfulness Walking Intervention to Enhance Resilience (iWalk)","A Randomized Controlled Trial of a Walking Meditation Intervention (iWalk) to Enhance Resilience in Adults","iWalk","Inclusion Criteria:\n\n1. 18 years or older,\n2. clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc.,\n3. have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs,\n4. never received meditation training via coaching\u002Fcertification\u002Flife coaching,\n5. have internet access,\n6. with no severe cognitive impairment, i.e., have a score of ≥ 21 on Modified Telephonic Interview for Cognitive Status (TICS-M),\n7. be able to walk with or without an assistive device (Patient determined Disease Steps score ranged from 0-6),\n8. are willing to be randomized to an intervention or a control group,\n9. are willing to wear Fitbit (a wrist smart watch) for eight weeks,\n10. are individuals who are right-handed according to the Edinburgh Handedness Questionnaire,\n11. are willing to participate in all assessments, including in-person testing using electroencephalography (EEG) and cognitive tests, online survey\u002Fquestionnaires, and online interviews or focus group discussions,\n12. are willing to wear a Hexoskin t-shirt, which is a heart rate variability monitor, while doing the assessments in person.\n\nExclusion Criteria:\n\nParticipants who cannot speak, read, write, or listen in English.","110 Years",{"count":368,"type":21},90,[126],"This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS).\n\nThe objectives are to evaluate:\n\n1. Recruitment capability and retention rates,\n2. Acceptability and adherence to the intervention,\n3. Feasibility of assessment procedures, and\n4. Preliminary effects on psychological, physiological, and behavioral outcomes.",[27,372,129,373],"EEG","Adults",[375,376,372],"Walking meditation","Emotional regulation","2025-12-02",{"date":379,"type":42},"2025-12-16",{"date":381,"type":42},"2025-06-01",{"date":383,"type":21},"2029-12-31",{"name":385,"class":147},"University of Illinois at Urbana-Champaign",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":124,"phases":396,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":48},"100296775","phase-2-pet-tau---neurodegenerative-disease-imaging-100296775","NCT03143374","PET Tau - Neurodegenerative Disease Imaging","Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease","INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS\n\n1. Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS\n2. Participants will be 18 years of age or older\n3. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.\n4. Participants must be willing and able to comply with scheduled visits and imaging procedures.\n5. Subject is concurrently enrolled in centers UNICORN(842873) protocol.\n\nINCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS\n\n1. Participants will be 18 years of age or older.\n2. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.\n3. Participants must be willing and able to comply with scheduled visits and imaging procedures.\n4. Subject is concurrently enrolled in centers UNICORN(842873) protocol\n\nEXCLUSION CRITERIA FOR ALL SUBJECTS\n\n1. Females who are pregnant or breast feeding at the time of the baseline PET\u002FCT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET\u002FCT.\n2. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician\n3. Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study\n4. The investigators may choose to exclude participants with clinically significant cardiovascular disease and\u002For documented abnormalities on ECG out of an abundance of caution.\n5. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.\n\nADDITIONAL EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS\n\n1. Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report.\n2. Current use of psychoactive medications or substances per medical record review or self-report.","100 Years",{"count":395,"type":21},300,[397,159],"PHASE2","The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET\u002FCT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).",[27],[27],"2025-10-10",{"date":403,"type":42},"2025-10-15",{"date":405,"type":42},"2016-08-23",{"date":407,"type":21},"2030-09",{"name":409,"class":147},"University of Pennsylvania",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":16,"sex":17,"minAge":417,"maxAge":393,"enrollmentInfo":418,"targetDuration":4,"studyType":124,"phases":420,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":4},"100587925","phase-1-vr-based-physical-activity-and-reminiscence-therapy-100587925","NCT06934720","VR-based Physical Activity and Reminiscence Therapy","Active Physical Activity - Virtual Reality Cognitive Therapy","Inclusion Criteria:\n\n* older adults in the setting who have the ability to pedal the rehabilitation bike\n\nExclusion Criteria:\n\n* Individuals self-reporting or identified by stakeholders as unwilling or unsuitable to participate.","60 Years",{"count":419,"type":21},100,[421,397],"PHASE1","The goal of this clinical trial is to learn if active Physical activity + virtual reality cognitive therapy (aPAVRCT) works to slow the progression of AD cognitive decline in older adults. It will also learn about the physical effects and mental effects of the aPAVRCT. The main questions it aims to answer are:\n\nDoes aPAVRCT slow the progression of AD cognitive decline? (e.g., HK-MoCA, ADAS-Cog) Does aPAVRCT improve physical function? (e.g., ADL) Does aPAVRCT improve mental health? (e.g., GDS-15, PANAS) Does aPAVRCT improve life satisfaction? Does aPAVRCT improve other cognitive or physical capacities? What issues and benefits do participants and stakeholders (e.g., families, caregivers, managers) have when taking aPAVRCT? (e.g., NPI-Q) Researchers will compare the intervention group (aPAVRCT) to a control group (rehabilitation bike) to see if aPAVRCT works to slow the progression of AD in cognitive decline.\n\nParticipants will:\n\nTake aPAVRCT (interventional group) or usual physical acitvity (control group) at least twice a week, 15 minutes for each session, for 12-16 weeks Physiotherapies (assistants) and care professionals will do the intervention, research group will operate, observe, and assist the experiment.\n\nAll the experiment processes will be recorded. Visit the sites everyday for checkups and tests Keep a diary of their symptoms, the number of times, and any essential information\n\nSites: around 3-5 nursing homes, under one institution. Inclusion criteria: older adults in the setting who have the ability to pedal a rehabilitation bike.",[72,27,424,425,426,427,428],"Mild Cognitive Impairment (MCI)","Virtual Reality","Physical Activity","Alzheimer's Disease (AD)","Cognitive Therapy","2025-05-18",{"date":431,"type":42},"2025-05-22",{"date":433,"type":21},"2025-05-19",{"date":435,"type":21},"2027-04-15",{"name":437,"class":147},"Hong Kong University of Science and Technology",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":307},"100275728","amyotrophic-lateral-sclerosis-and-the-innate-immune-system-100275728","NCT02869048","Amyotrophic Lateral Sclerosis and the Innate Immune System","Inclusion Criteria:\n\n* For ALS group:Diagnosed with the diagnose category \"certain ALS\" or \"likely ALS according to the El Escorial rev. diagnose criteria\n* For Neurological control group: Referred to neurological department to be examined for acute or chronic headache or referred to get a lumbar perfusion test performed.\n\nExclusion Criteria:\n\n* For all groups (Clinical study 2-3): permanent contraindication for having a lumbar puncture performed\n* For Neurological control group: Known with chronic inflammatory disease or autoimmune disease.\n* For healthy control group (clinical study 1): Known with any disease\n* For healthy control group (clinical study 1): Taking daily medication\n* For Neurologically healthy control group (Clinical study 2): Known with neurological disease\n* For Neurologically healthy control group (Clinical study 2): Known with chronic inflammatory disease or autoimmune disease.",{"count":445,"type":21},375,"Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it is necessary with respiratory therapy in order to breathe. In average an ALS patient lives 3 years from the time he or she gets the diagnose.\n\nThe cause of the disease is still unknown and there is currently no treatment which can stop the progression of the disease. Former clinical studies have indicated that the innate immune system and in particular the complement system plays a significant role in the progression of ALS. The complement system, which is activated in cascades, is part of the innate system but participates in the innate as well as the acquired immune system. Former clinical trials have been characterized by limited knowledge about both the complement system as well as to how it is measured.\n\nToday it is possible to measure directly on the different components of the complement system and to understand its contribution to the overall immune response. It is also possible today to detect defects of the complement system. All these progressions are the foundation for this project which is carried out in close cooperation with one of the world's leading researchers in the complement system, professor Peter Garred from Rigshospitalet.\n\nThe aim is to make a national research project about ALS in order to investigate the role of the innate immune system, and especially the complement system, in patients with ALS.\n\nIn the long term the hope is, that this will lead the way to a targeted and effective medical treatment to the people affected by this grave disease.",[448,27,449],"Amyotrophic Lateral Sclerosis","Motor Neuron Disease",[451,452,453,454,455,456,457],"Biological Specimen Banks","Innate Immunity","Clinical Study","Complement system proteins","Amyotrophic lateral sclerosis","Neurodegenerative disease","Motor neuron disease","2017-10-04",{"date":460,"type":42},"2017-10-06",{"date":462,"type":4},"2016-06",{"date":464,"type":21},"2026-06",{"name":466,"class":147},"Rigshospitalet, Denmark"]